Compare KMI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMI | ARGX |
|---|---|---|
| Founded | 1936 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.1B | 58.4B |
| IPO Year | 2010 | 2017 |
| Metric | KMI | ARGX |
|---|---|---|
| Price | $31.18 | $1,021.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 19 |
| Target Price | $33.69 | ★ $1,008.56 |
| AVG Volume (30 Days) | ★ 9.7M | 293.1K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.74% | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $16,937,000,000.00 | N/A |
| Revenue This Year | $5.43 | $44.39 |
| Revenue Next Year | $4.52 | $20.84 |
| P/E Ratio | $37.80 | ★ $33.69 |
| Revenue Growth | ★ 12.17 | N/A |
| 52 Week Low | $25.60 | $661.85 |
| 52 Week High | $34.81 | $1,058.69 |
| Indicator | KMI | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.14 | 68.00 |
| Support Level | $26.38 | $830.58 |
| Resistance Level | $33.02 | N/A |
| Average True Range (ATR) | 0.68 | 27.02 |
| MACD | -0.09 | 16.17 |
| Stochastic Oscillator | 14.12 | 85.11 |
Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.